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Abstract
 
Tumor-specific CD8
 
 
 
 T cells can potentially be activated by two distinct mechanisms of major
histocompatibility complex class I–restricted antigen presentation as follows: direct presentation
by tumor cells themselves or indirect presentation by professional antigen-presenting cells
(APCs). However, controversy still exists as to whether indirect presentation (the cross-priming
mechanism) can contribute to effective in vivo priming of tumor-specific CD8
 
 
 
 T cells that
are capable of eradicating cancer in patients. A clinical trial of vaccination with granulocyte
macrophage–colony stimulating factor–transduced pancreatic cancer lines was designed to test
whether cross-presentation by locally recruited APCs can activate pancreatic tumor-specific
CD8
 
 
 
 T cells. Previously, we reported postvaccination delayed-type hypersensitivity (DTH)
responses to autologous tumor in 3 out of 14 treated patients. Mesothelin is an antigen demon-
strated previously by gene expression profiling to be up-regulated in most pancreatic cancers.
We report here the consistent induction of CD8
 
 
 
 T cell responses to multiple HLA-A2, A3,
and A24-restricted mesothelin epitopes exclusively in the three patients with vaccine-induced
DTH responses. Importantly, neither of the vaccinating pancreatic cancer cell lines expressed
HLA-A2, A3, or A24. These results provide the first direct evidence that CD8 T cell responses
can be generated via cross-presentation by an immunotherapy approach designed to recruit
APCs to the vaccination site.
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Introduction
 
A major goal of vaccine development is to design immuni-
zation strategies that activate CD8
 
 
 
 T cells. CD8
 
 
 
 T cells
are the effector cells most capable of directly recognizing
and lysing their target, whether it be a virally infected cell
or a tumor cell. Activation of CD8
 
 
 
 T cells requires target
cell presentation of antigen on MHC class I (1). In a host
with cancer, tumor cells can present endogenous MHC
class I–restricted antigens to CD8
 
 
 
 T cells by direct presen-
tation. However, the APCs of the host, rather than the tumor
cells themselves, can also process and present acquired tumor
antigens captured from the tumor’s microenvironment, to
prime CD8
 
 
 
 T cells. The mechanism of transferring exog-
enously acquired antigens from the APC endocytic processing
and presentation pathway into the cytosol for processing
and presentation via the proteosome (the endogenous pro-
cessing and presentation pathway) is referred to as cross-
priming (2–10).
Many preclinical studies have demonstrated that APCs
have the ability to capture dying cells, and process and
present captured antigens expressed by these cells to CD8
 
 
 
T cells (5, 8, 11–16). Several groups have shown that the
DC, in particular, exhibits efficient cross-priming in both
human and mouse models in vitro (6, 17). Although cross-
priming has been confirmed as a mechanism by which
CD8
 
 
 
 T cells can be primed in vitro, controversy still exists
concerning the efficiency of this mechanism at priming
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CD8
 
 
 
 T cells in vivo (18). In several murine tumor mod-
els, Zinkernagel et al. found that, whereas MHC class II–
restricted antigens were efficiently cross-presented, CTL
activation occurred exclusively via direct presentation of
MHC class I–restricted antigens by the tumor (18). A bet-
ter understanding of the role of the cross-priming mecha-
nism in the induction of CD8
 
 
 
 T cells in vivo will have
important implications for future vaccine development.
Several cancer vaccine approaches under clinical develop-
ment specifically aim to recruit and activate DCs as a first
step in priming both CD4
 
 
 
 and CD8
 
 
 
 T cells (19, 20). The
unique capacity of DCs to stimulate tumor-reactive T cell
lines from cancer patients emphasizes the importance of the
cell type in recruiting cryptic populations of tolerant or low
affinity T cells into an antitumor response (21). In particular,
whole cell vaccine approaches have already demonstrated
that the APCs of the host, rather than the vaccinating tumor
cells themselves, can prime both CD4
 
 
 
 and CD8
 
 
 
 T cells
that are capable of generating systemic antitumor immunity
against transplanted murine tumors in vivo (14, 22, 23). It
has been more difficult to prove that cross-priming is in-
volved in the induction of clinically meaningful CD8
 
 
 
 T
cell responses in patients. The major impediment has been
the lack of correlation of immunization and the induction
of T cell responses in reported studies.
In a recently completed phase I trial, a vaccine consisting
of two allogeneic, GM-CSF–secreting pancreatic tumor
cell lines induced a dose-dependent delayed-type hyper-
sensitivity (DTH) response to autologous tumor cells in 3
out of 14 patients (24). A whole cell tumor vaccine ap-
proach allows for polyvalent immunizations under circum-
stances where relevant tumor rejection antigens have not
yet been identified. This allogeneic GM-CSF–secreting
pancreatic tumor vaccine was specifically designed to test
whether GM-CSF can recruit APCs, in particular DCs, to
the site of vaccination and subsequently prime CD8
 
 
 
 T
cells by the cross-priming mechanism. To determine whether
this vaccine induced CD8
 
 
 
 T cell responses and to study
the mechanism of activation of these responses, we have
developed a functional genomic approach that uses immu-
nized lymphocytes from vaccinated patients to identify im-
munologically recognized tumor-associated antigens from
among genes overexpressed in the relevant tumor type.
Here, we identify a pancreatic tumor-associated antigen,
mesothelin, as a relevant target of vaccine-induced CD8
 
 
 
T cell responses. We use these responses to directly evalu-
ate the capacity of the GM-CSF–transduced vaccines to in-
duce cross-priming in pancreatic cancer patients.
 
Materials and Methods
 
Identification of Candidate Genes and Epitope Selection. 
 
Serial
analysis of gene expression (SAGE) was used to identify mesothe-
lin as one of the genes overexpressed in pancreatic cancer cell
lines and fresh tissue (25, 26). Two computer algorithms “BI-
MAS” (27) and “SYFPEITHI” (28) that are available to the gen-
eral public and accessible through the internet were used to pre-
dict peptides that bind to HLA-A2, A3, and A24 molecules.
 
Peptides and T2 Cell Lines. 
 
All peptides were purified to
 
 
 
95% purity and synthesized by Macromolecular Resources ac-
cording to the following published sequences: M1 peptide
 
(58–66)
 
GILGFVFTL, derived from influenza matrix protein (29); me-
sothelin A2
 
(20–28)
 
 peptide SLLFLLFSL; mesothelin A2 
 
(530–538)
 
 pep-
tide VLPLTVAEV, identified using the available databases; and
HIV-gag A2 peptide SLYNTVATL
 
(75–83)
 
 (30), which contains an
HLA-A2 binding motif. Mesothelin A3
 
(83–91)
 
 peptide ELAVA-
LAQK
 
,
 
 mesothelin A3
 
(225–233)
 
 peptide ALQGGGPPY, and HIV-
NEF A3
 
(94–103)
 
 peptide QVPLRPMTYK (31) contain an HLA-A3
binding motif. Mesothelin A24
 
(435–443)
 
 peptide FYPGYLCSL, me-
sothelin A24
 
(475–483)
 
 peptide LYPKARLAF, and tyrosinase peptide
AFLPWHRLF
 
(206–214)
 
 (32) contain an HLA-A24 binding motif.
The mesothelin A1
 
(309–317)
 
 peptide EIDESLIFY was used as a neg-
ative control peptide and contains an HLA-A1 binding motif.
Stock solutions (10 mg/ml) of peptides were prepared in 100%
DMSO (JTBaker) and further diluted in cell culture medium to
yield a final peptide concentration of 10 ng/ml for each assay. The
T2 cells are a human B and T lymphoblast hybrid that only ex-
presses the HLA-A
 
*
 
0201 allele (33). T2 cells are TAP deficient
and, therefore, fail to transport newly processed HLA class I bind-
ing epitopes from the cytosol into the endoplasmic reticulum,
where these epitopes would normally bind to nascent HLA mole-
cules and stabilize them for expression on the cell surface (33). The
T2-A3 are T2 cells genetically modified to express the HLA-
A
 
*
 
0301 allele and were a gift from W. Storkus (University of Pitts-
burgh, Pittsburgh, PA; reference 34). The T2-A24 are T2 cells ge-
netically modified to express the HLA-A24 allele. The HLA-A24
gene was a gift from P. Robbins (National Cancer Institute, Be-
thesda, MD; reference 32). T2 cells were grown in suspension cul-
ture in RPMI 1640 (GIBCO BRL), 10% FBS (Hyclone) supple-
mented with 200 
 
 
 
M 
 
l
 
-glutamine (JRH Biosciences), 50 U/
 
 
 
g/
ml of Pen/Strep (Sigma-Aldrich), 1% NEAA (Sigma-Aldrich), and
1% Na-Pyruvate (Sigma-Aldrich) in 5% CO
 
2
 
 at 37
 
 
 
C.
 
Peptide/MHC Binding Assays.
 
T2 cells expressing the HLA
molecule of interest were resuspended in AimV serum-free media
(GIBCO BRL) to a concentration of 10
 
6
 
 cells/ml and pulsed with
 
 
 
-2 microglobulin (
 
 
 
2
 
-M) plus peptide at concentrations ranging
from 0 to 225 
 
 
 
g/ml of peptide at room temperature overnight.
The level of stabilized MHC on the cell surface of the T2 and T2-
A24 cells was analyzed by direct staining of cell samples with unla-
beled anti–class I mAb W6/32 and a goat anti–mouse FITC-
labeled IgG2a secondary antibody. The level of stabilized MHC
on the cell surface of the T2-A3 cells was analyzed by direct stain-
ing of cell samples with unlabeled anti–HLA-A3 mAb GAPA3
and a goat anti–mouse FITC-labeled IgG2a secondary antibody.
Viable cells, as determined by exclusion of propidium iodide,
were analyzed by flow cytometry on a dual laser FACSCalibur™
(Becton Dickinson) using FlowJo analysis software (Treestar).
Data are expressed as an increase in mean fluorescence intensity
(
 
 
 
MFI) of cells with each peptide compared with that determined
for cells without peptide or a negative control peptide.
 
PBLs and Donors. 
 
Peripheral blood (100 cc prevaccination
and 28 d after each vaccination) were obtained from all 14 pa-
tients who received an allogeneic GM-CSF–secreting pancreatic
tumor vaccine as part of a previously reported phase I vaccine
analysis (24). Informed consent for banking lymphocytes to be
used for this antigen identification study was obtained at the time
of patient enrollment into the study. Pre- and postvaccine PBLs
were isolated by density gradient centrifugation using Ficoll-
Hypaque (Amersham Biosciences). Cells were washed twice with
serum-free RPMI 1640. PBLs were stored frozen at 
 
 
 
140
 
 
 
C in
90% AIM-V media containing 10% DMSO. 
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Enrichment of PBLs for CD8
 
 
 
 T Cells. 
 
CD8
 
 
 
 T cells were
isolated from thawed PBLs using magnetic cell sorting of human
leukocytes as per the manufacturer’s directions (MACS; Miltenyi
Biotec). Cells were fluorescently stained with CD8-PE antibody
(Becton Dickinson) to confirm that the positive population con-
tained CD8
 
 
 
 T cells and analyzed by flow cytometry. This pro-
cedure consistently yielded 
 
 
 
95% CD8
 
 
 
 T cell purity.
 
CD8
 
 
 
 M1-specific T Cell Lines. 
 
M1-specific T cell lines
were generated by repeated in vitro stimulation of HLA-
A
 
*
 
0201
 
 
 
 PBLs initially with irradiated autologous dendritic cells
followed by irradiated autologous EBV-transformed B cells, both
pulsed with the HLA-A
 
*
 
0201–restricted epitope. T cells were
stimulated at a 1:2 T cell/EBV cell ratio in T cell media consist-
ing of RPMI 1640, 10% human serum (pooled serum collected at
the Johns Hopkins University Hemapheresis Unit), 200 
 
 
 
M
 
l
 
-Glutamine, 50 U/
 
 
 
g/ml Pen/Strep, 10 mM Hepes (GIBCO
BRL) supplemented with 60 international units IL-2/ml (R&D
Systems), and 10 ng/well IL-7 (R&D Systems). This line was
used as a positive control T cell line in all assays.
 
ELISPOT Assay. 
 
Multiscreen 96-well filtration plates (Mil-
lipore) were coated overnight at 4
 
 
 
C with 60 
 
 
 
l/well of 10 
 
 
 
g/
ml anti–hIFN-
 
 
 
 mouse Mab 1-D1K (Mabtech). Wells were
washed three times each with PBS and blocked for 2 h with T
cell media. 10
 
5
 
 T2 cells pulsed with 10 ng/ml of peptide in 100
 
 
 
l of T cell media were incubated overnight with 10
 
5
 
 thawed
PBLs that were purified to select CD8
 
 
 
 T cells in 100 
 
 
 
l T cell
media on the ELISPOT plates in replicates of six. The plates
were incubated overnight at 37
 
 
 
C in 5% CO
 
2
 
. Cells were re-
moved from the ELISPOT plates by washing six times with
PBS 
 
 
 
 0.05% Tween 20 (Sigma-Aldrich). Wells were incubated
for 2 h at 37
 
 
 
C in 5% CO
 
2
 
 using 60 
 
 
 
l/well of 2 
 
 
 
g/ml of bio-
tinylated Mab anti–hIFN-
 
 
 
 7-B6-1 (Mabtech). The avidin per-
oxidase complex (Vectastain ELITE ABC kit; Vector Laborato-
ries) was added after washing six times with PBS/Tween 0.05%
at 100 
 
 
 
l/well and incubated for 1 h at room temperature. AEC
substrate solution (3-amino-9-ethylcarbazole) was added at 100
 
 
 
l/well and incubated for 4–12 min at room temperature. Color
development was stopped by washing with tap water. Plates were
dried overnight at room temperature, and colored spots were
counted using an automated image system ELISPOT reader
(Axioplan2; Carl Zeiss Microimaging, Inc.).
 
Flow Cytometry. 
 
The cell lines were washed twice and resus-
pended in FACS
 
®
 
 buffer (HBSS supplemented with 1% PBS, 2%
FBS, and 0.2% sodium azide), stained with mouse monoclonal
mesothelin (CAK1; Signet Laboratories) followed by FITC-
labeled goat anti–mouse IgG1 (BD Biosciences) for flow analysis
in a FACScan™ analyzer (BD Immunocytometry Systems).
 
In Vitro Generation of Tumor-reactive CTLs.
 
Purified mono-
cytes were cultured for 4 d in the presence of 100 ng/ml recom-
binant human GM-CSF (R&D Systems) and 10 ng/ml rhIL-4
(R&D Systems) in complete RPMI 1640 medium (35). The
monocytes were activated overnight by incubation with 0.5 
 
 
 
g/
ml LPS (Sigma-Aldrich). The tissue culture–generated mono-
cytes were pulsed with 30 
 
 
 
g/ml of synthetic peptides together
with 3 
 
 
 
g/ml 
 
 
 
2
 
-M (Sigma-Aldrich) in PBS containing 1% hu-
man serum albumin (Sigma-Aldrich) for 4 h at room tempera-
ture. The peptide-pulsed DCs were washed twice, irradiated
(4,200 rad), and mixed with autologous CD8
 
 
 
 T cells (purified
with antibody-coated magnetic beads by positive selection;
Miltenyi Biotec) at a 1:10 (DC/T cell) ratio. This medium was
supplemented with 10 ng/ml rhIL-7 (R&D Systems). 1 d later,
60 international units/ml rhIL-2 (R&D Systems) were added to
the cultures to increase the efficiency of CTL induction. Approx-
imately every 10 d, the T cell cultures were restimulated with ir-
radiated peptide-pulsed autologous DCs as previously mentioned,
adding rhIL-7 and rhIL-2 on the same day. The cytotoxicity as-
says were performed after three rounds of peptide stimulation.
 
Chromium Release Assay. 
 
10
 
6
 
 target cells were labeled in 100
 
 
 
l complete medium and 100 
 
 
 
Ci 
 
51
 
Cr (Amersham Biosciences)
at 37
 
 
 
C for 1–1.5 h (36). To determine the mesothelin-specific
lysis from patient 13 CD8
 
 
 
 T cell line, 
 
51
 
Cr-labeled target cells
(3 
 
 
 
 10
 
3
 
) were added to varying concentrations of the CD8
 
 
 
 T
cell line in a total of 200 
 
 
 
l in a v-bottom 96-well plate for 4 h at
37
 
 C. Each data point was performed in triplicate and averaged.
Data are expressed as percentage of specific lysis   (measured re-
lease   spontaneous release)   (maximum release   spontaneous
release)   100. The spontaneous release ranged between 10 and
15% of the total label incorporated into the cells. For HLA-
blocking studies, either the pan-HLA antibody W6/32 (HB-95;
American Type Culture Collection) or the isotype matched anti–
Schistosoma mansoni antibody, MBL (HB-193; American Type
Culture Collection) were added to the target cells (50  g/ml) for
30 min at 37 C before adding the T cells.
Results
Vaccination with an Allogeneic Pancreatic Tumor Vaccine
Induces Mesothelin-specific CD8  T Cells. To determine
whether the cross-priming mechanism is functional and ef-
ficient in inducing CD8  T cells in pancreatic cancer pa-
tients receiving an allogeneic, GM-CSF–secreting vaccine,
we first needed to identify pancreatic tumor antigens
against which vaccine-induced immune responses are elic-
ited. A growing number of genes shown to be differentially
expressed in pancreatic adenocarcinomas using SAGE have
been tabulated and reported (25, 26, 37). We screened this
SAGE analysis database to identify genes that can also serve
as potential immune targets for the majority of pancreatic
adenocarcinoma patients. We focused specifically only on
those genes that were nonmutated, overexpressed by the
majority of pancreatic cancer patients, and overexpressed
by the vaccine cell lines (all being important requirements
for evaluating CD8  T cell cross-priming). One gene that
met all three criteria was mesothelin (25), the focus of this
paper. We used the combination of two public-use com-
puter algorithms (27, 28, 35) to predict peptide nonamers
that bind to three common HLA class I molecules. Both
computerized algorithms score candidate epitopes based on
amino acid sequences within a given protein that have sim-
ilar binding motifs to previously published HLA-binding
epitopes. We synthesized the top two ranking mesothelin
epitopes for HLA-A2, HLA-A3, and HLA-A24 favored by
both algorithms because at least one of these three HLA
class I molecules is expressed by each of the 14 patients that
were treated in the vaccine paper (24). The human T2 cell
line, which expresses empty MHC class I molecules on its
surface because it is TAP transporter deficient, was used to
confirm epitope binding to MHC class I (33). Binding of
these epitopes to their respective HLA class I molecule was
confirmed by pulsing TAP-deficient T2 cells that expressed
the corresponding HLA class I molecule (T2-A2, T2-A3,
or T2-A24 cells). As shown in Fig. 1 A, pulsing of two me-Evidence of Cross-Priming in Vaccinated Pancreatic Cancer Patients 300
sothelin-derived epitopes predicted to bind to HLA-A2
allowed for detection of HLA-A2 on the cell surface of
T2-A2 cells by flow cytometry after staining with the
HLA class I–specific antibody, W6/32. In contrast, T2
cells pulsed with a mesothelin epitope predicted to bind
to HLA-A1 do not stain with the same antibody. Bind-
ing of T2 cells pulsed with two candidate mesothe-
lin-derived HLA-A3 and two candidate HLA-A24
epitopes demonstrated similar results (Fig. 1, B and C,
respectively).
To determine if mesothelin is recognized by CD8  T
cells, we screened antigen-pulsed T2 cells in a quantitative
ELISPOT-based assay using pre- and postvaccination CD8 
T cell–enriched PBLs from the 14 patients treated previ-
ously with the allogeneic, GM-CSF–secreting pancreatic
tumor vaccine. Previously, we reported the association of in
vivo postvaccination DTH responses to autologous tumor
in three out of eight patients receiving the highest two doses
of vaccine. PBLs obtained before vaccination and 28 d after
the first vaccination were initially analyzed. T2-A3 cells
pulsed with the two A3 binding epitopes were incubated
overnight with CD8  T cell–enriched lymphocytes isolated
from the peripheral blood of patients 11 (an A3 non-DTH
responder) and 13 (an A3 DTH responder), and analyzed
using an IFN-  ELISPOT assay. The ELISPOT assay was
chosen because it requires relatively few lymphocytes, is
among the most sensitive in vitro assays for quantitating an-
tigen-specific T cells, and correlates the number of antigen-
specific T cells with function (cytokine expression; refer-
ences 38–40). Induction of mesothelin-specific T cells was
detected 28 d after vaccination in patient 13, a DTH re-
sponder, but not in patient 11, a non-DTH responder (Fig.
2 A). Similarly, postvaccination induction of mesothelin-
specific CD8  T cells was also observed in the two other
disease-free DTH responders (patient 8 [HLA-A2/A3] and
patient 14 [HLA-A24]), but not in other non-DTH re-
sponders when tested with T2-A2/A3 (patient 2) and T2-
A24 (patient 7) cells pulsed with the A2, A3 (Fig. 2 B), and
A24 (Fig. 2 C) binding epitopes, respectively. A summary of
the ELISPOT results evaluating vaccine-induced mesothe-
lin-specific CD8  T cell responses for all 14 patients treated
with one allogeneic vaccination in this analysis is shown in
Fig. 2 D. This difference in detection of mesothelin-specific
T cell responses is statistically significant at a P   0.001 by
the Fisher exact test. These data suggest that there is a direct
correlation between observed postvaccination in vivo DTH
responses to autologous tumor and postvaccination in vivo
mesothelin-specific CD8  T cell responses for patients
treated with an allogeneic vaccine in this paper. Specifically,
each of the three DTH responders demonstrated a postvac-
cination induction in CD8  T cell responses to two differ-
ent mesothelin peptides that matched their respective HLA
type, whereas only 1 out of 11 DTH nonresponders had an
increased postvaccination mesothelin-specific CD8  T cell
response and only to a single peptide.
Poor Immune Status Does Not Explain the Failure to Measure
Vaccine-induced, Mesothelin-specific CD8  T Cell Responses in
DTH Nonresponders. The data in Fig. 2 correlate in vivo
DTH responses to autologous tumor with the postvaccina-
tion induction of mesothelin-specific CD8  T cell re-
sponses. However, it is possible that this correlation repre-
sents generalized differences in overall immune function
between the DTH responder and nonresponder patients,
rather than a vaccine-specific induction of T cell responses
to mesothelin in the DTH responder patients. To demon-
strate that the postvaccination induction of mesothelin-spe-
cific CD8  T cells is tumor antigen specific, we evaluated
each HLA-A2  patient for T cell responses to the HLA-A2
binding influenza matrix peptide, M1 (29). We chose the
influenza M1 peptide because most patients on the vaccine
analysis had received yearly influenza vaccines as a standard
of care before enrollment. As shown in Fig. 3, all HLA-
Figure 1. T2 binding assay identifies mesothelin protein-derived
epitopes that bind to HLA-A2, A3, and A24 molecules. T2 cells were
pulsed with 0–225  g/ml of peptide overnight at room temperature before
analysis by flow cytometry. (A) T2 cells expressing HLA-A2 and pulsed
with either a mesothelin A1(309–317) peptide (closed diamond), mesothelin
A2(20–28) (closed square), and mesothelin A2(530–538) (closed triangle). (B) T2
cells genetically modified to express HLA-A3 and pulsed with either
mesothelin A1(309–317) peptide (closed diamond), mesothelin A3(83–91)
(closed square), and mesothelin A3(225–233) (closed triangle). (C) T2 cells
genetically modified to express HLA-A24 and pulsed with either mesothe-
lin A1(309–317) peptide (closed diamond), mesothelin A24(435–443) (closed
square), and mesothelin A24(475–483) (closed triangle). Thomas et al. 301
A2  patients demonstrated similar pre- and postvaccination
T cell responses to the M1 peptide. Prevaccination re-
sponses ranged from 19 to 50 IFN-  spots per 105 total
CD8 T cells, and postvaccination responses remained ap-
proximately the same in each patient, unaffected by immu-
nization with the pancreatic tumor vaccine (Fig. 3). A sim-
ilar analysis confirmed that the HLA-A3 and HLA-A24
patients have detectable CD8  T cell responses to influenza
and EBV peptides (27, 28, 41), respectively, and that these
responses are unaltered by immunization with the alloge-
neic pancreatic tumor vaccine (unpublished data).
In Vivo Cross-priming Explains the Induction of Mesothelin-
specific CD8  T Cells in Patients Vaccinated with the Allogeneic
Pancreatic Tumor Vaccine. Vaccine-induced in vivo prim-
ing of host T cells by allogeneic tumor cells can occur by
one of two mechanisms. The allogeneic tumor cells might
directly prime the host’s CD8  T cells if the immunizing
cells express HLA class I molecules in common with the
host’s HLA type. If not, transfer of the tumor antigen from
the allogeneic cells to professional APCs would be re-
quired. Murine studies have already demonstrated that both
Figure 2. ELISPOT analysis of CD8  T cells from PBMCs demon-
strates postvaccination induction of mesothelin-specific T cells in three
DTH responders. (A) ELISPOT analysis of PBLs from two patients who
were HLA-A3 . (B) ELISPOT analysis of PBLs from two patients who
were HLA-A-2 and HLA-A3 . (C) ELISPOT analysis of PBLs from two
patients who were HLA-A24 . (D) ELISPOT analysis of PBLs from all
14 patients who were treated with the vaccine (reference 24). ELISPOT
analysis for IFN- –expressing cells was performed using PBMCs that
were isolated on the day before vaccination or 28 d after the first vaccina-
tion. T2-A3 cells were pulsed with the two mesothelin-derived epitopes
MesoA3(83–91) (squares), MesoA3(225–233) (X), and HIV-NEF(94–102) (not
shown). T2-A2 cells were pulsed with the two mesothelin-derived
epitopes MesoA2(20–28) (triangles), MesoA2(530–538) (circles), and HIV-
gag(77–85) (not shown). T2-A24 cells were pulsed with the two mesothelin-
derived epitopes MesoA24(435–443) (asterisks), MesoA24 (475–483) (diamonds),
and tyrosinase A24(206–214) (not shown). All DTH responders are repre-
sented by dotted lines and open symbols, and DTH nonresponders are
represented by solid lines and closed symbols. For the detection of non-
specific background, the number of IFN-  spots for CD8  T cells spe-
cific for the irrelevant control peptides were counted. The HLA-A2
binding HIV-gag protein-derived epitope (SLYNTVATL), the HLA-A3
binding HIV-NEF protein-derived epitope (QVPLRPMTYK), and the
HLA-A24 binding tyrosinase protein-derived epitope (AFLPWHRLF)
were used as negative control peptides in these assays. Background was
minimal to negative control peptides, ranging from zero to three spots total
(data included in each graph). Data represent the mean of each condition
assayed in triplicate, and standard deviations were  5%. The number of
human IFN-  spots per 105 CD8  T cells is plotted. Analysis of each patient’s
PBLs was performed at least twice.
Figure 3. ELISPOT analysis of CD8  T cells from PBMCs demon-
strates similar pre- and postvaccination responses to the influenza matrix
protein HLA-A2 binding epitope M1 (GILGFVFTL) in all HLA-A2 
patients This analysis was performed on the same PBL samples described
in Fig. 2. The DTH responders are represented by dotted lines, and the
DTH nonresponders are represented by solid lines. For the detection of
nonspecific background, the number of IFN-  spots for CD8  T cells
specific for the irrelevant control peptides were counted. The HLA-A2
binding HIV-gag protein-derived epitope (SLYNTVATL), the HLA-A3
binding HIV-NEF protein-derived epitope (QVPLRPMTYK), and the
HLA-A24 binding melanoma tyrosinase protein-derived epitope (AFLP-
WHRLF) were used as negative control peptides in these assays. Data
represent the mean of each condition assayed in triplicate, and standard
deviations were  5%. The number of human IFN-  spots per 105 CD8 
T cells is plotted. Analysis of each patient’s PBLs was performed at least
twice, and all ELISPOT assays were performed in a blinded fashion.Evidence of Cross-Priming in Vaccinated Pancreatic Cancer Patients 302
mechanisms can contribute to the induction of systemic
antitumor immunity (42). However, controversy still re-
mains as to whether vaccination can result in the induction
of antigen-specific CD8  T cells via the cross-priming
mechanism that are efficient enough and in large enough
quantities to treat actively growing cancer in patients. In
this paper, we have evaluated the induction of HLA-A lo-
cus-restricted, mesothelin-specific CD8  T cells in patients
who received an allogeneic vaccine that is mismatched at
the HLA-A locus (Table I). Specifically, we have demon-
strated the induction of mesothelin-specific CD8  T cells
to HLA-A2, A3, and A24 mesothelin-derived peptides in
patients receiving a mixture of two allogeneic pancreatic
tumor vaccines. Both of these vaccine lines overexpress
mesothelin (Fig. 4). However, neither vaccine line ex-
presses HLA-A2, A3, or A24 (Table I). Therefore, these
data provide direct evidence at the epitope level that allo-
geneic vaccine cells can activate CD8  T cells against shared
pancreatic tumor antigens, and that these CD8  T cell re-
sponses are associated with other measures of in vivo im-
mune responses. Because the vaccine cells are HLA mis-
matched with the three DTH responders’ at the HLA-A
locus, CD8  T cell activation must occur by transfer of
MHC class I antigens from the tumor cells to professional
APCs, where they are processed and presented on MHC
class I molecules via cross-priming.
Cross-Priming by Vaccine Recruited APCs Results in the
Generation of Mesothelin-specific CD8  T Cells Capable of Lysing
Mesothelin-expressing Tumor Cells. The most important
role of vaccine-induced CD8  T cells in vivo is the ulti-
mate lysis of antigen-expressing tumors. Currently, the best
measure of this aspect of CD8  T cell function is the ability
of isolated CD8  T cells to lyse antigen-expressing tumors
in vitro. In an effort to correlate IFN-  release with lytic
activity in response to mesothelin, we analyzed the reactiv-
ity of a patient-derived T cell line to a panel of HLA-A3 
and HLA-A3  tumor cell lines in a 4-h chromium release
assay. The level of mesothelin expression of these tumor
lines is shown in Fig. 4. Autologous DCs pulsed with the
HLA-A3 mesothelin peptide 6293 were used to expand
patient 13 CD8  mesothelin-specific T cells in vitro. Cy-
tolytic activity was assessed after three in vitro stimulations
against HLA-A3  and HLA-A3  mesothelin-expressing
target cells. As shown in Fig. 5 A, mesothelin-specific
CD8  T cells were able to lyse autologous EBV-trans-
formed B cells transduced with the mesothelin gene,
T2-A3 cells pulsed with the HLA-A3 mesothelin peptide
6293, and an HLA-A3 , mesothelin-expressing allogeneic
tumor cell line, Panc 3.014. In a second study, lysis of the
Panc 3.014 line could be blocked by the pan-HLA block-
ing antibody W6/32, but not by the isotype matched an-
tibody against S. mansoni (unpublished data). In contrast,
mesothelin-specific, patient-derived CD8  T cells did not
lyse well the mesothelin-expressing HLA-A3  tumor cell
line Panc 3.11, nor the HLA-A3-expressing, mesothelin-
negative cell lines Panc 2.5 and the nonmesothelin-express-
ing autologous EBV-transformed B cells. After repeated in
vitro stimulation, the T cell line lysed the Panc 3.014
mesothelin and HLA-A3–expressing line well (which was
genetically modified to express HLA-A3), but not the orig-
inal HLA-A3 , mesothelin-expressing Panc 3.014 tumor
cell line (Fig. 5 B). These studies have been repeated six
times with similar lysis results. These data confirm that an
allogeneic vaccine can induce mesothelin-specific CD8  T
cell responses via the cross-priming mechanism, and that
these CD8  T cells are capable of lysing mesothelin-
expressing cell line.
Discussion
These data describing CD8  T cell responses induced
by an allogeneic GM-CSF–secreting pancreatic tumor vac-
Figure 4. Expression of surface mesothelin of both the Panc 6.03 and
Panc 10.05 vaccine and on cell lines used as targets for CTL assays. Panc
6.03, Panc 10.05, autologous EBV, autologous EBV transduced with
mesothelin, Panc 2.5 (HLA-A3 ), Panc 3.014 (HLA-A3 ), and Panc
3.11 (HAL-A3 ) were analyzed by flow cytometry for their levels of sur-
face mesothelin using the mesothelin-specific monoclonal antibody
CAK1 as the primary antibody and goat anti–mouse IgG1 FITC as the
secondary antibody. The dotted line represents the isotype control, and
the solid line represents mesothelin staining.
Table I. HLA Mismatch with the Vaccine Cells at the HLA-A Locus Provide Direct Human Evidence for MHC Class I Antigen 
Cross-Priming by APCs
Vaccine line
Panc 10.05
Vaccine line
Panc 6.03 Patient 8 Patient 13 Patient 14
HLA class I expression at the A locusa A1, A19 A1, A1 A2, A3 A3, A23 A1, A24
aHLA typing was performed serologically and confirmed molecularly.Thomas et al. 303
cine support the following two conclusions. First, these
findings provide direct human evidence that allogeneic
vaccine cells induce CD8  T cell responses by a cross-
priming mechanism that requires transfer of antigen from
the vaccine cells to professional APCs. Second, mesothelin
is a new candidate pancreatic tumor antigen that can be
used to analyze immune responses induced by whole cell
pancreatic tumor vaccines.
The identification of shared, biologically relevant tumor
antigens provides the opportunity to study the mechanisms
by which vaccines induce antitumor immune responses.
An important result of this paper is the direct demonstra-
tion of cross-priming at the MHC class I epitope level.
Controversy still exists as to whether cross-priming is a
clinically important mechanism for in vivo priming of
CD8  T cells (18). Previously published murine studies
evaluating whole cell vaccines have shown that the profes-
sional APCs of the host can prime both CD4  and CD8 
T cells, both of which are required for generating systemic
antitumor immunity (14, 22, 23). Furthermore, Jung et al.
have previously shown that cross-priming is relevant in
vivo because depletion of CD11C  DC abrogated effective
immunization in mice (43). Cross-priming has also been
shown to play an important role in generating CD8  T cell
responses to infectious diseases (44–46). Furthermore, hu-
man tumor studies have demonstrated that both macro-
phages and DCs can take up antigens in vitro and prime
naive CD8  T cells by the cross-priming mechanism (5, 8,
11–16, 44–46). However, other studies suggest that the
mechanism of cross-priming is inefficient at inducing
CD8  T cell responses in vivo in vaccinated healthy sub-
jects (47). Several factors may explain the differences in
results between these studies. First, the efficiency of cross-
priming in vivo may be influenced by several factors, in-
cluding the following: the route of APC exposure to the
antigen (44), whether the APC is a macrophage or DC (6,
17, 47), the maturation status of the APCs (48), and the
form of antigen taken up by the APCs (4, 11). The form of
the antigen that is presented to the APCs has been of par-
ticular interest because several recent studies suggest that
apoptotic tumors are more efficiently processed and pre-
sented by an APC than necrotic tumor or soluble protein
(8, 11). Furthermore, we have reported previously that ir-
radiated GM-CSF–secreting vaccine cells are much more
efficient at inducing systemic immune responses than unir-
radiated vaccine cells or vaccine cells that are inactivated by
nonapoptotic inducing mechanisms (49). In addition, sev-
eral studies have used the ovalbumin antigen system, which
is a strong foreign antigen that may be processed and pre-
sented differently than naturally occurring tumor-associated
antigens (4, 6).
The biologic importance of these data in demonstrating
CD8  T cell cross-priming is strongly supported by our
data correlating these responses with in vivo postvaccina-
tion DTH responses to autologous tumor cells. Until now,
observed postvaccination DTH responses against autolo-
gous tumor cells has provided the best evidence in support
of a vaccine-induced, T cell–mediated antitumor immunity
in patients treated in clinical trials (24, 50–57). Three re-
cent papers have linked antibody responses to clinical re-
sponses in patients receiving a melanoma vaccine (58, 59)
and a human chorionic gonadotropin–based vaccine (60).
However, this paper also demonstrates postvaccination in
vitro antigen-specific T cell responses that correlate with in
vivo evidence of immune induction (DTH responses to
autologous tumor cells). In addition, the use of uncultured
lymphocytes rather than T cell lines and clones that have
been in long-term culture demonstrates immune responses
that are more closely associated with human in vivo T cell
function. Unfortunately, it is difficult to demonstrate direct
pancreatic cell killing without several rounds of in vitro
CD8  T cell expansion. However, after three rounds of
stimulation with autologous DCs pulsed with the A3 me-
sothelin peptide, these T cells can lyse a pancreatic tumor
line and other mesothelin-expressing cell lines, providing
evidence that mesothelin can serve as a tumor rejection tar-
get of T cells. Only a small panel of tumor lines were tested
due to the significant challenge in generating in vitro pan-
creatic tumor lines, including the three DTH responder
patients. However, the fact that the T cells lyse mesothelin-
expressing HLA-A3  tumor cells, but not mesothelin-
expressing HLA-A3  lines, demonstrates the mesothelin
and HLA-restricted specificity of the T cell activity.
Figure 5. A mesothelin-specific CTL line derived from patient 13 PBL
lyses HLA-A3 , mesothelin-expressing cells. Patient-derived CD8  T
cells stimulated with an HLA-A3 mesothelin peptide (peptide 6293) were
tested for their capability to recognize and kill mesothelin-expressing tumor
and EBV cell lines shown in Fig. 4. 51Cr-labeled target cells (3   103)
were mixed with varying concentrations of patient 13 CD8  T cell line
(starting with 9   104) in a total of 200  l in a v-bottom 96-well plate.
Percent lysis was calculated after 4 h at 37 C. Results are expressed as the
percentage of specific lysis of triplicate samples.Evidence of Cross-Priming in Vaccinated Pancreatic Cancer Patients 304
In this paper, we also demonstrate that mesothelin-spe-
cific T cells can be induced against at least six different pep-
tides presented by three different HLA-A locus alleles. T
cell responses determined by ELISPOT were comparable
for each of the epitopes. This finding provides further sup-
port that mesothelin can serve as a shared antigen. This
finding also provides further evidence that cross-priming is
an efficient mechanism for antigen processing and presenta-
tion onto MHC class I. It is interesting to point out that the
highest-ranking antigenic epitopes predicted to be the best
HLA-A allele binding epitopes based on their motif, bound
to their respective HLA alleles and were also recognized by
mesothelin-specific T cells. Papers analyzing other tumor
antigens have found that the highest ranking epitopes do
not necessarily correlate with optimal recognition by T
cells (35). We also performed the computer algorithms on
two melanoma antigens, tyrosinase and MAGE 1, to deter-
mine how their published HLA-A2 binding peptides rank
by this method (61, 62). We found that our HLA-A2 bind-
ing mesothelin epitopes were given similar scores as the
known tyrosinase and MAGE 1 HLA-A2 binding epitopes.
This was also true for the published HLA-A2 HIV-gag and
HLA-A3 HIV-NEF epitopes that were used as control an-
tigens in our analyses (30, 31). Choosing epitopes that rank
high by both algorithms appears to be an important predic-
tor of the probability of binding to the respective HLA
molecule. However, the likelihood of successfully predict-
ing HLA binding epitopes will probably be determined in
part by the antigen being studied. Studies aimed at address-
ing this question are underway.
In conclusion, we have directly demonstrated cross-
priming at the MHC class I epitope level. These studies
were facilitated through the development of a functional
genomic approach that identified mesothelin as a new can-
didate pancreatic tumor antigen recognized by CD8  T
cells. The correlation of in vitro T cell responses with in
vivo measures of immunologic response validates the bio-
logic importance of this approach. Because we detected ev-
idence for cross presentation in the three patients with a
better clinical course, we suspect that cross-presentation
may have clinical relevance, but larger studies are required
to investigate this.
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